What is claimed is:

1. A method of qualifying ischaemic heart disease status in a subject comprising:

(a) measuring at least one biomarker in a sample from the subject, wherein the biomarker is selected from the group consisting of galectin-3 and galectin-3 fragments, and

(b) correlating the measurement with ischaemic heart disease status.

2. The method of claim 1, further comprising:

(c) managing subject treatment based on the status.

3. The method of claim 2, wherein managing subject treatment is selected from ordering more tests, performing surgery, prescribing medication, and taking no further action.

4. The method of claim 2, further comprising:

(d) measuring at least one biomarker after subject management.

5. The method of claim 1, wherein the ischaemic heart disease status is selected from the group consisting of the presence or absence of disease, the degree of disease and the effectiveness of treatment of disease.

6. The method of claim 5, further comprising measuring at least one additional biomarker selected from the group consisting of fibrinogen and fibrinogen fragments and correlating measurement of the biomarkers measured with ischaemic heart disease status.

7. The method of claim 1, wherein measuring comprises:

(a) providing a subject sample of blood or a blood derivative;

(b) fractionating proteins in the sample and collecting fractions that contain galectin-3 or a galectin-3 fragment biomarker; and

(c) capturing the biomarkers from the fractions on a surface of a substrate comprising capture reagents that bind the biomarkers.

8. The method of claim 7, wherein the substrate is a SELDI probe comprising an adsorbent that captures the biomarkers and wherein the biomarkers are detected by SELDI.

9. The method of claim 8, wherein the SELDI probe comprises a biospecific affinity reagent that binds the biomarkers.

10. The method of claim 7, wherein the substrate is a microtiter plate comprising biospecific affinity reagents that bind the biomarkers and the biomarkers are detected by immunoassay.

11. The method of claim 1, wherein measuring is selected from detecting the presence or absence of the biomarkers(s), quantifying the amount of marker(s), and qualifying the type of biomarker.

12. The method of claim 1, wherein at least one biomarker is measured using a biochip array.

13. The method of claim 12, wherein the biochip array is a protein chip array.

14. The method of claim 12, wherein at least one biomarker is immobilized on the biochip array.

15. The method of claim 1, wherein the biomarkers are measured by SELDI.

16. The method of claim 1, wherein the biomarkers are measured by immunoassay.

17. The method of claim 1, wherein the correlating is performed by a software classification algorithm.

18. The method of claim 1, wherein the sample is selected from blood, serum and plasma.

19. A method comprising measuring a plurality of biomarkers in a sample from the subject, wherein the biomarkers are selected from the group consisting of galectin-3 and galectin-3 fragments.

20. The method of claim 19, further comprising measuring an additional biomarker selected from the group consisting of fibrinogen and fibrinogen fragments.

21. The method of claim 20, wherein a plurality of the additional biomarkers are measured.

22. The method of claim 19, wherein the biomarkers are detected by SELDI or immunoassay.

23. The method of claim 19, wherein the sample is selected from blood, serum and plasma.

24. A method comprising measuring at least one biomarker in a sample from a subject, wherein the biomarker is selected from the group consisting of galectin-3 and galectin-3 fragments.

25. The method of claim 24, further comprising measuring an additional biomarker selected from the group consisting of fibrinogen and fibrinogen fragments.

26. The method of claim 25, wherein a plurality of the additional biomarkers are measured.

27. The method of claim 24, wherein the biomarkers are detected by SELDI or immunoassay.

28. The method of claim 24, wherein the sample is selected from blood, serum and plasma.

29. A kit comprising:

(a) a capture reagent that binds a biomarker selected from galectin-3 and galectin-3 fragments; and

(b) instructions for using the capture reagent to detect the biomarker.

30. The kit of claim 29, additionally comprising:

(c) a container comprising at least one of the biomarkers.

31. The kit of claim 29, wherein the capture reagent binds a plurality of the biomarkers.

32. The kit of claim 29, wherein the capture reagent is a SELDI probe.

33. The kit of claim 29, further comprising an additional capture reagent that binds an additional biomarker selected from the group consisting of fibrinogen and fibrinogen fragments.

34. The kit of claim 33, wherein the additional capture reagent binds a plurality of the additional biomarkers.

35. The kit of claim 33, wherein the additional capture reagent is a SELDI probe.

36. The kit of claim 33, wherein the capture reagent is an antibody

37. The kit of claim 36, wherein the capture reagent is an anti-galectin-3 antibody.

38. The kit of claim 36, wherein the capture reagent is an anti-troponin I antibody.

39. The kit of claim 33, wherein the additional capture reagent is an antibody.

40. The kit of claim 33, wherein the additional capture reagent is an anti-fibrinogen antibody.

41. The kit of claim 33, wherein the additional capture reagent is an anti-troponin I antibody.

42. The kit of claim 33, wherein the additional capture reagent is an anti-galectin-3 antibody.

43. The kit of claim 29, comprising a SELDI probe to which the capture reagent is attached or is attachable.

44. The kit of claim 33, comprising a SELDI probe to which the additional capture reagent is attached or is attachable.

45. The kit of claim 29, further comprising a wash solution that selectively allows retention of bound biomarker to the capture reagent as compared with other proteins after washing.

46. A kit comprising:

(a) a single capture reagent that binds both a biomarker selected from the group consisting of galectin-3 and galectin-3 fragments and an additional biomarker selected from the group consisting of fibrinogen and fibrinogen fragments; and

(b) instructions for using the capture reagent to detect both of the biomarkers.

47. The kit of claim 46, additionally comprising:

(c) a container comprising at least one of the biomarkers.

48. The kit of claim 46, additionally comprising:

(c) at least one container comprising at least on of the biomarkers; and

(d) at least one container comprising at least one of the additional biomarkers.

49. The kit of claim 46, wherein the capture reagent is an antibody.

50. The kit of claim 49, wherein the capture reagent is an anti-troponin antibody.

51. The kit of claim 49, wherein the capture reagent is an anti-galectin-3 antibody.

52. The kit of claim 46, comprising a SELDI probe to which the capture reagent is attached or is attachable.

53. The kit of claim 46, further comprising a wash solution that selectively allows retention of bound biomarkers to the capture reagent as compared with other proteins after washing.

54. The kit of claim 46, further comprising written instructions for use of the kit in the diagnosis of ischaemic heart disease.

55. The kit of claim 47, wherein the instructions provide for contacting the biomarker(s) in container (c) with the capture reagent and describe the result of the contacting.

56. The kit of claim 48, wherein the instructions provide for contacting the biomarkers in containers (c) and (d) with the capture reagent and describe the result of the contacting.